Today's Daily Dose brings you news about the upcoming key milestones of Stealth BioTherapeutics; the extended partnership between Natural Alternatives and The Juice Plus+ Company; Merrimack's discontinuation of phase I study of MM-310 for the treatment of solid tumors; and Sangamo's pricing of its public offering.
from RTT - Biotech http://bit.ly/2IeSkaL
via IFTTT
No comments:
Post a Comment